These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 8510922)

  • 1. Single point mutations in the SH2 domain impair the transforming potential of vav and fail to activate proto-vav.
    Katzav S
    Oncogene; 1993 Jul; 8(7):1757-63. PubMed ID: 8510922
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutagenic analysis of Vav reveals that an intact SH3 domain is required for transformation.
    Groysman M; Nagano M; Shaanan B; Katzav S
    Oncogene; 1998 Sep; 17(12):1597-606. PubMed ID: 9794237
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rac-1 dependent stimulation of the JNK/SAPK signaling pathway by Vav.
    Crespo P; Bustelo XR; Aaronson DS; Coso OA; Lopez-Barahona M; Barbacid M; Gutkind JS
    Oncogene; 1996 Aug; 13(3):455-60. PubMed ID: 8760286
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tyrosine phosphorylation of vav proto-oncogene product containing SH2 domain and transcription factor motifs.
    Margolis B; Hu P; Katzav S; Li W; Oliver JM; Ullrich A; Weiss A; Schlessinger J
    Nature; 1992 Mar; 356(6364):71-4. PubMed ID: 1531699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vav: Captain Hook for signal transduction?
    Katzav S
    Crit Rev Oncog; 1995; 6(2):87-97. PubMed ID: 8792085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vav and Ras induce fibroblast transformation by overlapping signaling pathways which require c-Myc function.
    Katzav S; Packham G; Sutherland M; Aroca P; Santos E; Cleveland JL
    Oncogene; 1995 Sep; 11(6):1079-88. PubMed ID: 7566967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vav cooperates with Ras to transform rodent fibroblasts but is not a Ras GDP/GTP exchange factor.
    Bustelo XR; Suen KL; Leftheris K; Meyers CA; Barbacid M
    Oncogene; 1994 Aug; 9(8):2405-13. PubMed ID: 8036025
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanism of activation of the vav protooncogene.
    Coppola J; Bryant S; Koda T; Conway D; Barbacid M
    Cell Growth Differ; 1991 Feb; 2(2):95-105. PubMed ID: 2069873
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduced phosphotyrosine binding by the v-Src SH2 domain is compatible with wild-type transformation.
    Tian M; Martin GS
    Oncogene; 1996 Feb; 12(4):727-34. PubMed ID: 8632894
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vav transformation requires activation of multiple GTPases and regulation of gene expression.
    Palmby TR; Abe K; Karnoub AE; Der CJ
    Mol Cancer Res; 2004 Dec; 2(12):702-11. PubMed ID: 15634759
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vav: function and regulation in hematopoietic cell signaling.
    Bonnefoy-Bérard N; Munshi A; Yron I; Wu S; Collins TL; Deckert M; Shalom-Barak T; Giampa L; Herbert E; Hernandez J; Meller N; Couture C; Altman A
    Stem Cells; 1996 May; 14(3):250-68. PubMed ID: 8724692
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Product of vav proto-oncogene defines a new class of tyrosine protein kinase substrates.
    Bustelo XR; Ledbetter JA; Barbacid M
    Nature; 1992 Mar; 356(6364):68-71. PubMed ID: 1311423
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutation of a phenylalanine conserved in SH3-containing tyrosine kinases activates the transforming ability of c-Abl.
    Jackson PK; Paskind M; Baltimore D
    Oncogene; 1993 Jul; 8(7):1943-56. PubMed ID: 8510937
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insulin-like growth factor-1 induces rapid tyrosine phosphorylation of the vav proto-oncogene product.
    Uddin S; Yetter A; Katzav S; Hofmann C; White MF; Platanias LC
    Exp Hematol; 1996 Apr; 24(5):622-7. PubMed ID: 8605967
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sequence specificity in the recognition of the epidermal growth factor receptor by the abl Src homology 2 domain.
    Zhu G; Decker SJ; Maclean D; McNamara DJ; Singh J; Sawyer TK; Saltiel AR
    Oncogene; 1994 May; 9(5):1379-85. PubMed ID: 8152798
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The product of the cph oncogene is a truncated, nucleotide-binding protein that enhances cellular survival to stress.
    Velasco JA; Avila MA; Notario V
    Oncogene; 1999 Jan; 18(3):689-701. PubMed ID: 9989819
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Src homology 2 domain substitution modulates the kinase and transforming activities of the Fes protein-tyrosine kinase.
    Rogers JA; Cheng HY; Smithgall TE
    Cell Growth Differ; 2000 Nov; 11(11):581-92. PubMed ID: 11095247
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vav: a potential link between tyrosine kinases and ras-like GTPases in hematopoietic cell signaling.
    Hu P; Margolis B; Schlessinger J
    Bioessays; 1993 Mar; 15(3):179-83. PubMed ID: 8489524
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Retroviral transduction and oncogenic selection of a cDNA encoding Dbs, a homolog of the Dbl guanine nucleotide exchange factor.
    Whitehead I; Kirk H; Kay R
    Oncogene; 1995 Feb; 10(4):713-21. PubMed ID: 7862449
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Isolation and characterization of murine vav2, a member of the vav family of proto-oncogenes.
    Schuebel KE; Bustelo XR; Nielsen DA; Song BJ; Barbacid M; Goldman D; Lee IJ
    Oncogene; 1996 Jul; 13(2):363-71. PubMed ID: 8710375
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.